To assess the effects of a combined blockade of VEGFR/PDGFR/FGFR in CRC on tumor growth we employed a xenograft tumour model of VEGF-expressing human colorectal cancer cells (LS174T) under Nintedanib inhibition. Here, PDGFRB is linked to colorectal cancer.